Skip to content
lifestyle.lincolnlabs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AtaiBeckley Inc.
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
July 6, 2026
AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
June 25, 2026
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
May 12, 2026
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
April 23, 2026
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
March 10, 2026